NEW YORK – Finish life sciences firm Medix Biochemica said Wednesday that it has acquired German immunoassay developer Candor Bioscience for an undisclosed amount.
Medix said the acquisition adds to its portfolio of raw materials used for in vitro diagnostics development and improves its ability to support immunoassay developers.
Candor offers a variety of reagents necessary for immunoassay development, including HAMA and interference blockers, surface blockers, stabilizers, and buffer solutions. Medix is a provider of raw materials to the IVD industry, producing and supplying antibodies, antigens, and other key materials.
"The partnership with Candor strengthens Medix Biochemica's ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers," Medix CEO Steve Ferguson said in a statement.
Following the close of the transaction, Candor's operations will remain in Wangen im Allgäu, Germany.